Psoriasis: diagnosis and management in Australian general practice

Psoriasis is a chronic immune-mediated inflammatory skin disease affecting approximately 2–3% of Australian adults, with bimodal age peaks at 15–25 and 50–60 years. Men and women are affected equally. The most common presentation — chronic plaque psoriasis (~80% of cases) — produces well-demarcated erythematous plaques with silvery scale, typically on extensor surfaces (elbows, knees), the scalp, lower back, and nails.

The underlying driver is the Th17 / IL-23 / IL-17 axis, with TNF-α amplification producing keratinocyte hyperproliferation and the characteristic plaques. This chronic systemic inflammation confers independent cardiovascular risk, drives psoriatic arthritis (PsA) in roughly 25% of patients, and substantially elevates the risk of depression, anxiety, and suicidality. The Australasian College of Dermatologists and Therapeutic Guidelines (eTG) both emphasise that psoriasis is not merely a skin disease — it is a multisystem inflammatory condition requiring proactive management of comorbidities alongside skin disease control.

Psoriasis is highly treatable. The treatment landscape has advanced substantially over the past decade, from topical agents and conventional systemics to a growing range of highly effective PBS-listed biologics and targeted oral agents.

A. Core clinical — the AU general-practice framework

Subtypes and severity

Clinical subtypes:

• Chronic plaque psoriasis (~80%) — well-demarcated erythematous plaques with silvery scale; symmetrical extensor surfaces, scalp, and lower back.
• Guttate psoriasis — abrupt-onset raindrop-pattern small plaques; typically post-streptococcal; more common in young adults; often self-limiting.
• Flexural (inverse) psoriasis — moist erythematous plaques in skin folds (axillae, inframammary folds, groin, natal cleft); minimal scale; mimics intertrigo or tinea.
• Nail psoriasis (~50% of patients with skin disease) — pitting, onycholysis, oil-drop sign, subungual hyperkeratosis; harbinger of psoriatic arthritis.
• Scalp psoriasis — common; often refractory; may extend beyond the hairline.
• Generalised pustular psoriasis (von Zumbusch) — sterile pustules, fever, systemic upset — medical emergency.
• Erythrodermic psoriasis — >90% body surface area involvement; fluid loss, hypothermia, cardiac strain — medical emergency.
• Psoriatic arthritis — inflammatory arthritis affecting ~25% of patients; may precede or occur without active skin disease.

Severity grading:

• Mild — less than 3% body surface area (BSA) or limited special sites (face, hands, feet, nails, genitals), DLQI below 10.
• Moderate — 3–10% BSA or special sites with significant impact, DLQI 10–20.
• Severe — greater than 10% BSA, or moderate-severe disease with DLQI above 20, or disease refractory to topical therapy; eligible for systemic or biologic treatment.

History

Per RACGP clinical resources and eTG Dermatology:

• Onset, distribution, duration, and course — acute flare vs chronic stable vs relapsing-remitting.
• Joint symptoms — the PEST questionnaire (5 items: pain, enthesitis, stiffness, dactylitis, nail changes); any positive screen warrants rheumatology referral.
• Triggers — streptococcal throat infection (guttate), skin trauma (Koebner phenomenon), drugs (β-blockers, lithium, antimalarials, NSAIDs, IFN, abrupt systemic corticosteroid withdrawal), stress, alcohol, smoking, obesity.
• Medication history — prior treatments and responses; current topical agents; systemic immunosuppressants; vaccinations.
• Family history — psoriasis, PsA, IBD, autoimmune disease.
• Cardiovascular risk factors — smoking, blood pressure, lipids, diabetes, waist circumference.
• Mental health — depression, anxiety, suicidality; substantially elevated baseline risk in moderate-to-severe psoriasis.
• Comorbidities — IBD (3× general population risk), uveitis, metabolic syndrome, fatty liver disease.
• Pregnancy plans — several systemic agents are teratogenic; critical to document.

Examination

• Skin — plaques: morphology, distribution, BSA estimate; Auspitz sign (pinpoint bleeding on scale removal).
• Special sites — nails (pitting, onycholysis, oil-drop sign), scalp, palmoplantar surfaces, genital and intertriginous areas.
• Joints — tender and swollen joints; dactylitis (sausage digit); enthesitis (Achilles or plantar fascia tenderness); morning stiffness duration.
• Metabolic — BMI, waist circumference, blood pressure.
• Mood and suicide screen — document at every annual review.

Investigations

Psoriasis is a clinical diagnosis in most patients. Investigations are directed at:

• Pre-systemic / pre-biologic screen (mandatory before initiating systemic or biologic therapy):
  • Hepatitis B (HBsAg, anti-HBs, anti-HBc) and hepatitis C serology
  • HIV serology
  • IGRA / Quantiferon-Gold for latent TB — mandatory before all biologics and immunosuppressants
  • Varicella IgG and MMR serology — live vaccines must be given before biologic initiation
  • Fasting lipids, glucose, UEC, LFT, FBC — baseline and ongoing monitoring
• Cardiovascular and metabolic workup — Heart Health Check (MBS item 699) at appropriate intervals.
• Methotrexate monitoring — FBC, LFT, UEC monthly for the first 3 months then 3-monthly; FibroScan or Hepascore for hepatic fibrosis periodically.
• Acitretin — lipids, LFT, and pregnancy test before initiation; fasting lipids at weeks 4 and 8 initially.
• Throat swab and ASOT — for guttate psoriasis following a recent sore throat.
• Skin biopsy — if the diagnosis is uncertain.

B. Evidence appraisal — stepping up from topicals to biologics

The treatment of psoriasis follows a recognised step-up pathway, underpinned by eTG Dermatology and Australasian College of Dermatologists guidance.

Step 1 — Topical therapy (mild to moderate plaque psoriasis):

The combination of calcipotriol 50 mcg/g and betamethasone dipropionate 0.5 mg/g (Daivobet ointment; Enstilar aerosol foam) applied once daily is the most effective and convenient topical regimen for body plaque psoriasis. Once-daily application improves adherence compared with twice-daily regimens. Enstilar foam is well suited to scalp and flexural involvement. Both are available on the PBS general schedule.

Additional topical options include coal tar (5–10% solution or shampoo) for thick scale, salicylic acid 2–10% as a keratolytic, and topical calcineurin inhibitors (tacrolimus, pimecrolimus) off-label for facial and flexural psoriasis where steroid-related skin atrophy is a concern.

Step 2 — Phototherapy (moderate psoriasis):

Narrowband UVB (NB-UVB) phototherapy — 2–3 sessions weekly for 8–12 weeks — is effective for moderate widespread plaque psoriasis without the systemic immunosuppression of biologic therapy. Referral to a dermatologist with phototherapy facilities is required. Access can be limited outside metropolitan areas.

Step 3 — Conventional systemic agents (moderate to severe):

Agent	PBS status	Key monitoring and safety notes
Methotrexate (7.5–25 mg weekly + folic acid daily)	Authority Required for psoriasis	FBC/LFT/UEC monthly then 3-monthly; FibroScan periodically; teratogen — 3-month washout in both partners pre-conception
Ciclosporin (2.5–5 mg/kg/day)	Authority Required	Monthly BP, UEC, LFT; maximum 1–2 years continuous use due to nephrotoxicity
Acitretin (25–50 mg/day)	Authority Required	Pregnancy Category X — 3-year washout post-cessation in women of childbearing potential; lipids, LFT; mucocutaneous side effects
Apremilast (Otezla) (30 mg twice daily)	Authority Required for moderate-severe psoriasis	GI side effects (nausea, diarrhoea) common initially; monitor for depression and suicidality — signal identified in trial data

Step 4 — Biologic and targeted oral therapy (severe or refractory):

PBS Section 100 Authority is required, with specialist (dermatologist) initiation. All biologics require the pre-biologic safety screen detailed above.

Class	Agents	PBS status
Anti-TNF	Adalimumab, etanercept, infliximab, certolizumab	Section 100 Authority Required for severe psoriasis
Anti-IL-17A	Secukinumab, ixekizumab	Section 100 Authority
Anti-IL-17A/F	Bimekizumab (Bimzelx) — PBS-listed October 2023; dual IL-17A and IL-17F blockade; higher PASI 100 rates; oral candidiasis in ~10%	Section 100 Authority
Anti-IL-12/23	Ustekinumab	Section 100 Authority
Anti-IL-23 (p19)	Guselkumab, risankizumab, tildrakizumab	Section 100 Authority; generally highest PASI 90/100 clearance; longer dosing intervals
Oral TYK2 inhibitor	Deucravacitinib (Sotyktu) 6 mg daily — PBS Authority (Streamlined) from October 2023; POETYK PSO-1/PSO-2 trials (NEJM 2022) showed superiority over placebo and apremilast	Authority Streamlined

Pre-biologic checklist: Hepatitis B/C, HIV, TB (IGRA/Quantiferon), varicella IgG, MMR serology, baseline FBC/LFT/lipids. Live vaccines must be administered before biologic initiation; they are contraindicated while on biologic or JAK/TYK2 therapy.

Lifestyle adjuncts:

Jensen et al. (JAMA Dermatology 2013) demonstrated that dietary weight loss in overweight patients with psoriasis significantly improves disease severity and enhances biologic treatment response. Smoking cessation and alcohol moderation are also disease-modifying: both are recognised triggers for flares, and alcohol substantially raises the risk of hepatotoxicity on methotrexate and acitretin.

C. Comorbidities: cardiovascular risk, psoriatic arthritis, and mental health

Cardiovascular risk:

Psoriasis confers independent cardiovascular risk beyond conventional risk factors. Severe psoriasis is associated with cardiovascular disease risk broadly equivalent to that seen in type 2 diabetes. The Heart Foundation 2023 absolute cardiovascular risk guidelines apply to all patients with psoriasis; those with moderate-to-severe disease should have a formal cardiovascular risk assessment including Heart Health Check (MBS item 699). Address all modifiable risk factors systematically: smoking cessation, blood pressure management, statin therapy per guidelines, and blood glucose control.

Psoriatic arthritis (PsA):

PsA develops in approximately 25% of patients with psoriasis. Features include asymmetric peripheral arthritis, dactylitis (sausage-finger or toe), enthesitis (Achilles, plantar fascia), nail disease, and occasionally axial disease resembling ankylosing spondylitis. Joint damage may be present even before skin disease is clinically apparent. Annual PsA screening with the PEST questionnaire (or equivalent tool) is recommended in general practice. Any positive PEST screen, new joint swelling, or dactylitis warrants prompt rheumatology referral — joint damage is not reversible once established.

Mental health:

Depression and anxiety are substantially more prevalent in psoriasis than in the general population, driven by visible skin disease, social stigma, pain, itch, and quality-of-life impairment. Suicidality risk is also elevated. NPS MedicineWise and the Australasian College of Dermatologists recommend annual mental health screening in psoriasis. The GP is well placed to initiate a Mental Health Care Plan (MBS item 2715/2717) when depression or anxiety is identified. Effectively controlling skin disease commonly improves mental health, but independent psychological support is warranted in moderate-to-severe cases.

IBD, uveitis, and metabolic syndrome:

Inflammatory bowel disease (Crohn’s disease and ulcerative colitis) occurs at approximately three times the general population rate in psoriasis. Uveitis is a recognised association, particularly in patients with PsA. Metabolic syndrome — central obesity, dyslipidaemia, hypertension, and insulin resistance — is prevalent and bidirectionally related to psoriasis severity. These comorbidities warrant proactive annual screening and management.

D. Australian operations

PBS-listed agents

Per PBS Australia, topical agents including calcipotriol/betamethasone combinations (Daivobet, Enstilar), coal tar, and salicylic acid are on the general schedule. Conventional systemic agents (methotrexate, ciclosporin, acitretin, apremilast) require Authority. Biologics (anti-TNF, anti-IL-17, anti-IL-23, ustekinumab) and deucravacitinib require Section 100 or Authority with specialist-initiated prescribing.

MBS items

Per MBS Online:

• Standard consultations — items 23, 36, 44.
• GP Chronic Condition Management Plan (GPCCMP) — items 965/967 — psoriasis qualifies as a chronic condition; allied health referral (exercise physiologist, dietitian, psychologist, podiatrist) up to 5 visits per year.
• Mental Health Care Plan — items 2715/2717 — for depression, anxiety, or suicidality comorbidity; review item 2712.
• Heart Health Check — item 699 — cardiovascular risk assessment.
• Pathology — FBC (65070), LFT (66512), UEC (66500), lipids (66536), HbA1c (66551), hepatitis B/C, HIV, IGRA/Quantiferon, varicella IgG.
• 75+ Health Assessment — item 707 — comorbidity and medication review.
• ATSI Health Assessment — item 715 — psoriasis has higher prevalence in some First Nations communities; adapted management framework.

Vaccinations before and during immunosuppressive therapy

Before commencing biologic therapy or conventional immunosuppressants, ensure: annual influenza, up-to-date COVID-19, pneumococcal (single dose Prevenar 20 or equivalent), shingles (Shingrix — non-live, preferred on immunosuppression), hepatitis B if non-immune, and HPV per schedule. All live vaccines (varicella, MMR, BCG) must be administered at least 4 weeks before biologic initiation; they are contraindicated while on biologic or TYK2 therapy.

E. Special populations

Pregnancy. Most conventional systemic agents carry significant teratogenic risk. Methotrexate requires a 3-month washout before conception in both women and men. Acitretin is Pregnancy Category X with a mandatory 3-year washout in women post-cessation — this must be counselled and documented at initiation. Apremilast is avoided in pregnancy. Calcipotriol/betamethasone combinations are generally acceptable in pregnancy; avoid very potent topical corticosteroids applied over large areas in the first trimester. NB-UVB phototherapy is safe. Among biologics, certolizumab is preferred due to minimal placental transfer.

Children and adolescents. Paediatric psoriasis is managed along the same principles as adult disease; systemic agents require specialist paediatric dermatology input. Adolescents need particular attention to psychosocial impact — self-esteem, school participation, social relationships — and mental health screening. Guttate psoriasis in children often follows streptococcal pharyngitis; a throat swab and ASOT are warranted, and treatment of documented streptococcal infection may help resolve the episode.

Older adults. Ciclosporin is used with caution in older patients due to nephrotoxicity combining with age-related renal function decline. Methotrexate dosing requires careful titration and more frequent monitoring because of reduced renal clearance. Falls risk should also be assessed — chronic pain, sleep disruption, and some immunosuppressants all interact with balance and mobility in this age group.

When to escalate

Emergency presentation (same day):

• Generalised pustular psoriasis (von Zumbusch) — fever, sterile pustules, systemic upset; hospital emergency and urgent dermatology consultation.
• Erythrodermic psoriasis — greater than 90% BSA involvement; fluid imbalance, infection risk, cardiac strain; hospital emergency.

Urgent referral:

• Suspected or newly confirmed psoriatic arthritis — rheumatology; early intervention preserves joint function.
• Severe or rapidly progressing flare unresponsive to GP-level management.
• Biologic candidacy — dermatologist initiation is required for PBS Authority.
• Severe psychological distress or suicidality — priority mental health response.

Routine dermatology referral:

• Refractory moderate-to-severe plaque disease requiring phototherapy, systemic agents, or biologic therapy.
• Specialist guidance on biologic or systemic sequencing after partial response.

What this article is and is not

This is general health information based on current Australian general practice and specialist guidelines — Therapeutic Guidelines (eTG) Dermatology, Australasian College of Dermatologists, Australian Medicines Handbook (AMH), RACGP, and NPS MedicineWise. It does not constitute personal medical advice and does not create a doctor–patient relationship. Decisions about specific treatments, including biologic and systemic therapies, are made with your own dermatologist or GP.

For consumer resources: HealthDirect — Psoriasis, Better Health Channel — Psoriasis, Psoriasis Australia, Australasian College of Dermatologists.

---

Sources cited

1. Therapeutic Guidelines (eTG) — Dermatology: Psoriasis
2. Australasian College of Dermatologists — Psoriasis
3. Australian Medicines Handbook (AMH)
4. RACGP — Dermatology clinical resources
5. PBS — Topicals, methotrexate, apremilast, biologics, deucravacitinib
6. MBS Online — GPCCMP, MHCP, Heart Health Check, pathology items
7. HealthDirect — Psoriasis
8. Better Health Channel — Psoriasis
9. Psoriasis Australia
10. Heart Foundation — Absolute cardiovascular risk guidelines 2023
11. Jensen P et al. — Dietary weight loss and psoriasis severity (JAMA Dermatol 2013)
12. Armstrong AW et al. — Deucravacitinib in plaque psoriasis (POETYK PSO-1/PSO-2; NEJM 2022)
13. NPS MedicineWise